🚀 VC round data is live in beta, check it out!
BioLineRx Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioLineRx and similar public comparables like Annexin Pharmaceuticals, Coegin Pharm, Reviva Pharmaceuticals, Oncodesign Precision Medicine and more.
BioLineRx Overview
About BioLineRx
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Founded
2003
HQ
Employees
79
Website
Sectors
Financials (LTM)
EV
$591K
BioLineRx Financials
BioLineRx reported last 12-month revenue of $1M.
In the same LTM period, BioLineRx generated $1M in gross profit and had net loss of ($6M).
Revenue (LTM)
BioLineRx P&L
In the most recent fiscal year, BioLineRx reported revenue of $1M and EBITDA of ($252K).
BioLineRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $1M | XXX | $950K | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($252K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (21%) | XXX | XXX | XXX |
| EBIT Margin | (908%) | XXX | (872%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | (506%) | XXX | (100%) | XXX | XXX | XXX |
| Net Debt | — | — | $6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioLineRx Stock Performance
BioLineRx has current market cap of $11M, and enterprise value of $591K.
Market Cap Evolution
BioLineRx's stock price is $0.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $591K | $11M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioLineRx Valuation Multiples
BioLineRx trades at 0.5x EV/Revenue multiple, and (2.3x) EV/EBITDA.
EV / Revenue (LTM)
BioLineRx Financial Valuation Multiples
As of April 18, 2026, BioLineRx has market cap of $11M and EV of $591K.
Equity research analysts estimate BioLineRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioLineRx has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $591K | XXX | $591K | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (9.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioLineRx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioLineRx Margins & Growth Rates
BioLineRx's revenue in the last 12 month grew by 29%.
BioLineRx's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
BioLineRx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (21%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (106%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 299% | XXX | 332% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 705% | XXX | 686% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 952% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioLineRx Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioLineRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexin Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Coegin Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Reviva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncodesign Precision Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Chemomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioLineRx M&A Activity
BioLineRx acquired XXX companies to date.
Last acquisition by BioLineRx was on XXXXXXXX, XXXXX. BioLineRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioLineRx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioLineRx Investment Activity
BioLineRx invested in XXX companies to date.
BioLineRx made its latest investment on XXXXXXXX, XXXXX. BioLineRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioLineRx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioLineRx
| When was BioLineRx founded? | BioLineRx was founded in 2003. |
| Where is BioLineRx headquartered? | BioLineRx is headquartered in Israel. |
| How many employees does BioLineRx have? | As of today, BioLineRx has over 79 employees. |
| Who is the CEO of BioLineRx? | BioLineRx's CEO is Philip A. Serlin. |
| Is BioLineRx publicly listed? | Yes, BioLineRx is a public company listed on Tel Aviv Stock Exchange. |
| What is the stock symbol of BioLineRx? | BioLineRx trades under BLRX ticker. |
| When did BioLineRx go public? | BioLineRx went public in 2007. |
| Who are competitors of BioLineRx? | BioLineRx main competitors are Annexin Pharmaceuticals, Coegin Pharm, Reviva Pharmaceuticals, Oncodesign Precision Medicine. |
| What is the current market cap of BioLineRx? | BioLineRx's current market cap is $11M. |
| What is the current revenue of BioLineRx? | BioLineRx's last 12 months revenue is $1M. |
| What is the current revenue growth of BioLineRx? | BioLineRx revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of BioLineRx? | Current revenue multiple of BioLineRx is 0.5x. |
| Is BioLineRx profitable? | No, BioLineRx is not profitable. |
| What is the current net income of BioLineRx? | BioLineRx's last 12 months net income is ($6M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.